There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on High Tide (HITI), Taysha Gene Therapies (TSHA) and United Therapeutics (UTHR) with bullish sentiments.
High Tide (HITI)
Haywood analyst Neal Gilmer reiterated a Buy rating on High Tide today and set a price target of $8.00. The company’s shares closed last Wednesday at $2.52.
According to TipRanks.com, Gilmer is a 2-star analyst with an average return of
Currently, the analyst consensus on High Tide is a Strong Buy with an average price target of $5.66.
See Insiders’ Hot Stocks on TipRanks >>
Taysha Gene Therapies (TSHA)
Needham analyst Gil Blum reiterated a Buy rating on Taysha Gene Therapies today and set a price target of $12.00. The company’s shares closed last Wednesday at $6.81.
According to TipRanks.com, Blum is a 5-star analyst with an average return of
Taysha Gene Therapies has an analyst consensus of Strong Buy, with a price target consensus of $12.44.
United Therapeutics (UTHR)
TD Cowen analyst Joseph Thome assigned a Buy rating to United Therapeutics today and set a price target of $660.00. The company’s shares closed last Wednesday at $583.12.
According to TipRanks.com, Thome is a 5-star analyst with an average return of
United Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $636.15, a 7.9% upside from current levels. In a report issued on April 24, RBC Capital also maintained a Buy rating on the stock with a $707.00 price target.
Read More on HITI:
- High Tide’s Remexian Hits Record 7.6-Tonne Quarter in German Medical Cannabis Market
- High Tide Secures $40 Million Credit Term Sheet With Big 5 Canadian Bank
- High Tide Amends 2025 Executive Pay Disclosure to Correct Omissions and Update Incentives
- High Tide Launches Probe Into Potential Manipulation of Its Shares
- High Tide Marks 4/20 with New Canna Cabana Store in Caledonia, Ontario
